Original Publication Date: 1 June, 2016
Publication / Source: Immunotherapy
Authors: Hampig Raphael Kourie & Jean Klastersky
The next decade in cancer therapy will be marked by the expansion of immunotherapies, namely immune checkpoint inhibitors. The increasing number and combination of checkpoint inhibitors and the variety of their mechanisms of action and indications will most likely multiply the side effects associated with these therapies and make their management more complicated and diversified.